ReviewInternational journal of molecular sciences2020
Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- A predictive model for fusion gene positivity in treatment-naive advanced non-small cell lung cancer.Translational lung cancer research · 2026Article
- Preventive strategies against brain metastases: current state of the art and future directions.Neurological research and practice · 2026Review
- Central Nervous System Metastases from Primary Lung Carcinoma: Significance of RNA Fusion Testing and Early Versus Late Metastases.Journal of personalized medicine · 2025Article
- Molecular evolution of central nervous system metastasis and therapeutic implications.Trends in molecular medicine · 2025Review
- Cancer brain metastasis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Comprehensive analysis of genomic alterations and novel prognostic biomarkers, and establishment of prediction models of metastasis in metastatic non-small cell lung cancer.Journal of Cancer · 2025Article
- Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer.International journal of general medicine · 2025Review
- Editorial: Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research.Frontiers in oncology · 2025Article
- Upfront Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients with Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of a 10-Year Bi-institutional Experience.Cancer research and treatment · 2025Article
- Developing a predictive model and uncovering immune influences on prognosis for brain metastasis from lung carcinomas.Frontiers in oncology · 2025Article
- A Rare Case of Large-Cell Neuroendocrine Carcinoma Metastasizing to the Brain: A Case Report.Cureus · 2024Article
- The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions.Cancers · 2024Review
- A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases.International journal of molecular sciences · 2024Review
- Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer.Frontiers in oncology · 2024Review
- Management of brain metastases in non-small cell lung cancer without actionable driver mutations-the need to dive deeper in the right 'pool'.Translational lung cancer research · 2023Article
- Management Paradigm of Central Nervous System Metastases in NSCLC: An Australian Perspective.JTO clinical and research reports · 2023Review
- Metastasis Inhibition.International journal of molecular sciences · 2023Article
- Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases.JTO clinical and research reports · 2022Article
- Review
- Emerging strategies for treating metastasis.Nature cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
The management of non-small cell lung cancer (NSCLC) has transformed with the discovery of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene fusions or rearrangements form a unique sub-class, with anaplastic lymphoma kinase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.